Immunotherapy Approved for Platinum-resistant Gynecologic Cancers
Pembrolizumab plus paclitaxel, with or without bevacizumab, was approved for PD-L1-positive ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) as well as pembrolizumab and berahyaluronidase...